CO2024006206A2 - Composiciones farmacéuticas - Google Patents
Composiciones farmacéuticasInfo
- Publication number
- CO2024006206A2 CO2024006206A2 CONC2024/0006206A CO2024006206A CO2024006206A2 CO 2024006206 A2 CO2024006206 A2 CO 2024006206A2 CO 2024006206 A CO2024006206 A CO 2024006206A CO 2024006206 A2 CO2024006206 A2 CO 2024006206A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical compositions
- liquid pharmaceutical
- antibodies
- formulations
- directed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2115127.9A GB202115127D0 (en) | 2021-10-21 | 2021-10-21 | Formulations |
| PCT/EP2022/079185 WO2023067051A1 (en) | 2021-10-21 | 2022-10-20 | Formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024006206A2 true CO2024006206A2 (es) | 2024-05-30 |
Family
ID=78806159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0006206A CO2024006206A2 (es) | 2021-10-21 | 2024-05-16 | Composiciones farmacéuticas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250281403A1 (https=) |
| EP (1) | EP4419077A1 (https=) |
| JP (1) | JP2024539502A (https=) |
| KR (1) | KR20240099316A (https=) |
| CN (1) | CN118175989A (https=) |
| AR (1) | AR127420A1 (https=) |
| AU (1) | AU2022369042A1 (https=) |
| CA (1) | CA3235492A1 (https=) |
| CL (1) | CL2024001232A1 (https=) |
| CO (1) | CO2024006206A2 (https=) |
| GB (1) | GB202115127D0 (https=) |
| GE (2) | GEAP202416521A (https=) |
| IL (1) | IL312211A (https=) |
| MX (1) | MX2024004873A (https=) |
| PE (1) | PE20241192A1 (https=) |
| TW (1) | TW202330029A (https=) |
| WO (1) | WO2023067051A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100679A2 (en) | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
| GB201209096D0 (en) | 2012-05-24 | 2012-07-04 | Medical Res Council Technology | Compounds |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
-
2021
- 2021-10-21 GB GBGB2115127.9A patent/GB202115127D0/en not_active Ceased
-
2022
- 2022-10-20 PE PE2024000907A patent/PE20241192A1/es unknown
- 2022-10-20 KR KR1020247016677A patent/KR20240099316A/ko active Pending
- 2022-10-20 EP EP22809342.3A patent/EP4419077A1/en active Pending
- 2022-10-20 WO PCT/EP2022/079185 patent/WO2023067051A1/en not_active Ceased
- 2022-10-20 IL IL312211A patent/IL312211A/en unknown
- 2022-10-20 CN CN202280070452.XA patent/CN118175989A/zh active Pending
- 2022-10-20 CA CA3235492A patent/CA3235492A1/en active Pending
- 2022-10-20 AU AU2022369042A patent/AU2022369042A1/en active Pending
- 2022-10-20 TW TW111139754A patent/TW202330029A/zh unknown
- 2022-10-20 MX MX2024004873A patent/MX2024004873A/es unknown
- 2022-10-20 JP JP2024547821A patent/JP2024539502A/ja active Pending
- 2022-10-20 US US18/703,675 patent/US20250281403A1/en active Pending
- 2022-10-20 GE GEAP202416521A patent/GEAP202416521A/en unknown
- 2022-10-20 GE GEAP202216521A patent/GEP20257801B/en unknown
- 2022-10-20 AR ARP220102860A patent/AR127420A1/es unknown
-
2024
- 2024-04-19 CL CL2024001232A patent/CL2024001232A1/es unknown
- 2024-05-16 CO CONC2024/0006206A patent/CO2024006206A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3235492A1 (en) | 2023-04-27 |
| US20250281403A1 (en) | 2025-09-11 |
| IL312211A (en) | 2024-06-01 |
| PE20241192A1 (es) | 2024-06-03 |
| GEAP202416521A (en) | 2024-07-25 |
| AR127420A1 (es) | 2024-01-24 |
| CL2024001232A1 (es) | 2024-09-13 |
| WO2023067051A1 (en) | 2023-04-27 |
| KR20240099316A (ko) | 2024-06-28 |
| GB202115127D0 (en) | 2021-12-08 |
| MX2024004873A (es) | 2024-05-06 |
| JP2024539502A (ja) | 2024-10-28 |
| GEP20257801B (en) | 2025-09-25 |
| EP4419077A1 (en) | 2024-08-28 |
| TW202330029A (zh) | 2023-08-01 |
| CN118175989A (zh) | 2024-06-11 |
| AU2022369042A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000751A1 (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419) | |
| CL2019002664A1 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados. | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| EP3849568A4 (en) | ORGANOID COMPOSITIONS FOR THE PRODUCTION OF HEMATOPOIETIC STEM CELLS AND DERIVATIVES THEREOF | |
| UY37513A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
| MX2015009591A (es) | Amidas como moduladores de canales de sodio. | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| NI201400031A (es) | Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio | |
| MX2022015106A (es) | Proceso para preparar tapinarof. | |
| CL2023000223A1 (es) | Nuevos inhibidores selectivos de hdac6 basados en oxadiazol | |
| CO2021005509A2 (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
| CL2016003048A1 (es) | Analogos de panonina minimas sintesis y uso de los mismos. | |
| UY39390A (es) | Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo | |
| MX2023014398A (es) | Sales y cristales novedosos. | |
| CL2021002149A1 (es) | Formulación de afabicin, método para elaborar la misma | |
| MX2017002913A (es) | Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida. | |
| MX374295B (es) | Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus métodos de preparación y usos de la sal de maleato y formas cristalinas. | |
| AR115303A1 (es) | Moduladores de calpaína y usos terapéuticos de los mismos | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| MX2022002437A (es) | Metodos para la produccion de arginasa humana recombinante 1 y sus usos. | |
| PY2201650A (es) | Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos | |
| CO2024006206A2 (es) | Composiciones farmacéuticas | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| ECSP19091293A (es) | Nuevas formulaciones orales de belinostat |